Jose “Pepe” Carmona serves as the Chief Financial Officer (CFO) at ADC Therapeutics SA, a clinical-stage biotechnology company focused on the development and commercialization of novel antibody drug conjugates (ADCs) for the treatment of cancer. In his role as CFO, Carmona is responsible for overseeing the company's financial operations, strategic planning, and investor relations. His leadership has been instrumental in guiding ADC Therapeutics through its growth phases, including the successful completion of its initial public offering (IPO) in May 2020. Prior to joining ADC Therapeutics, Carmona held several high-profile positions in the biotechnology and pharmaceutical industries. He was the CFO at Spark Therapeutics, where he played a key role in the company's IPO and its eventual acquisition by Roche for $4.3 billion. Before Spark, Carmona served as CFO at Optimer Pharmaceuticals, which was acquired by Cubist Pharmaceuticals. His extensive experience in financial management and strategic planning in the biotech sector has been a significant asset to ADC Therapeutics. Carmona holds a Bachelor of Science in Accounting from Villanova University and an MBA from The Wharton School of the University of Pennsylvania. Under Carmona's financial stewardship, ADC Therapeutics has made significant strides in advancing its pipeline of ADCs, securing funding for clinical trials, and establishing partnerships with other industry leaders. His ability to navigate complex financial landscapes and drive growth has been crucial to the company's success. Carmona's strategic vision and dedication to advancing cancer treatment continue to position ADC Therapeutics as a leader in the biopharmaceutical industry.